Kornimate/medical-research-clean huggingface dataset:
comparative study of survival and long-term quality of life after cardiac surgery in patients who are jehovah's witnesses

Conditions: Cardiac Surgery

Summary: this is a comparative study on the survival and long-term quality of life of jehovah's witnesses having undergone a cardiac surgery and having refused blood transfusions for religious reasons. this group will be compared with two other groups having no restrictions on this subject. the purpose of the study is to evaluate the impact of this decision on survival and postoperative quality of life, in the long term.


Eligibility criteria:
inclusion criteria: * cardiac surgery with extra corporeal blood circulation * informed consent given exclusion criteria: * dementia (must be able to answer the questionnaire) * control group: refusal of blood transfusions
protective effect of coronary collaterals on infarct size in patients with acute myocardial infarction

Conditions: Myocardial Infarction

Summary: the hypothesis of the current proposal is that collateral flow is an important determinant of myocardial protection during an ischemic event. increased collateral flow for any given area at risk will decrease the myocardial damage caused by the occlusion of the infarct related epicardial artery. it is further hypothesized that myocardial salvage provided by collateral flow will decrease infarct size and this in turn will decrease lv dilatation post-myocardial infarction.

the hypothesis of the current proposal is that collateral flow is an important determinant of myocardial protection during an ischemic event. increased collateral flow for any given area at risk will decrease the myocardial damage caused by the occlusion of the infarct related epicardial artery. it is further hypothesized that myocardial salvage provided by collateral flow will decrease infarct size and this in turn will decrease lv dilatation post-myocardial infarction. the two primary endpoints are infarct size as assessed by increase of biochemical cardiac markers and coronary collateral perfusion index (cpi) as obtained by transthoracic mce. extent of lv remodelling, i.e., lv dilatation as assessed by serial assessment of lv dimension by lv angiogram and/or echocardiography, respectively.

Eligibility criteria:
inclusion criteria: * patients with acute myocardial infarction with electrocardiographic criterion and/or typical history of angina pectoris and planned revascularisation according to the acute myocardial infarction disease management guidelines of the university hospital bern. including both, patients undergoing primary pci and patients referred for rescue pci after failed thrombolytic therapy * patients \> 18 years old of either sex * patients who have given informed consent to the study exclusion criteria: * patients unable to give informed consent e.g. because of mechanical ventilation * patients with cardiogenic shock * patients with myocardial infarction secondary to occlusion of a recently revascularized vessel (subacute stent thrombosis) * patients with severe arrhythmias * patients whose door-to-balloon time exceeds 120 minutes * pregnancy

Keywords: myocardial infarction contrast echocardiography collateral circulation
a comparison of ticagrelor (azd6140) and clopidogrel in patients with acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: ticagrelor is a new, reversible binding, anti-platelet medication. anti-platelet medications work to prevent the formation of blood clots. ticagrelor is being developed as a treatment for patients with acute coronary syndrome (acs). acs is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. acs is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with acs.


Eligibility criteria:
inclusion criteria: * male or female 18 years or older who has been hospitalised for chest pain and potential acs * females of child-bearing potential must have a negative pregnancy test at enrollment and be willing to use 2 methods of reliable contraception exclusion criteria: * persons with moderate or severe liver disease * persons who have already been treated with an invasive (angioplasty) procedure for the current episode of acs * persons who are being treated with blood clotting agents that cannot be stopped

Keywords: acs acute coronary syndrome heart attack unstable angina coronary artery disease
kinesthetic ability trainer for peripheral neuropathic pain

Conditions: Neuropathic Pain

Summary: objective: to determine the effectiveness of balance training with kinesthetic ability trainer 2000 (kat 2000) in patients with peripheral neuropathic pain related balance disorder. methods: a total of 60 patients who developed peripheral neuropathic pain-related balance impairment in the chronic phase due to lumber disc herniation, lumber spondylosis and gonarthrosis were included into this randomized controlled prospective study and randomized into either balance exercises groups or kat 2000 exercises groups. balance exercises were given all patients in group 1 (n=30). in addition to balance exercises, kat 2000 balance exercises were given all patients in group 2 (n=30). all patients received 45-min individualized training session for three times a week for 4 weeks. patients were evaluated according to pain, static and dynamic balance and quality of life (qol).

neuropathic pain was determined by the douleur neuropathique 4 (dn4) questionnaire. pain severity was assessed by using a visual analogue scale (vas). kat 2000 was used to evaluate static and dynamic balance. dynamic balance and mobility also was assessed using the berg balance scale (bbs) and time up and go (tug) test. qol was assessed by using nottingham health profile (nhp). patients were evaluated at baseline and the end of the 4-week exercise program.

Eligibility criteria:
inclusion criteria: * dn4 scores ≥4 and moderately impaired balance with a score of 21-40 points on the berg balance scale. exclusion criteria: * who had history of previous cerebrovascular events; other neurological, musculoskeletal, inner ear or eye disease that may lead to impaired vision or standing balance.

Keywords: neuropathic pain balance kinesthetic ability trainer quality of life
essential fats for enhancing cognitive thinking (effect) study

Conditions: Cognitive Decline; Cognitive Impairment

Summary: the proposed research is a randomized crossover trial designed to assess changes in postprandial cognitive function and the gut-brain axis in adults with subjective cognitive complaints who consume 1 study snack per day for 1 week.

study objective including 1. to measure the impact of dietary fats on postprandial cognitive function in adults who report subjective cognitive complaints. 2. to assess the effect of dietary fat consumption on the gut-brain axis in relationship to cognitive function.

Eligibility criteria:
inclusion criteria: * subjective cognitive impairment * bmi ≥30 kg/m2 * hba1c \<6.5% exclusion criteria: * diagnosis og cognitive impairment or dementia * montreal cognitive assessment (moca) score of \<26 * current or previous diagnosis of diabetes or use of diabetes medications * current diagnosis of or current treatment of cancer other than non-melanoma skin cancer * gastrointestinal diseases or disorders (including pancreatic and gastric bypass surgery) where consumption of the study foods would be contraindication or where the disease or disorder could negatively affect nutrient absorption and/or would prevent participants from tolerating the study foods * hyperthyroidism diagnosis * food allergy or intolerances * any dietary restriction where consumption of the study foods, study meals/snack or meal challenge or any ingredient would be contraindicated * use of some oil supplements in the past 4 weeks prior to enrolling * pregnancy and lactation * inability to access veins for venipuncture * antibiotic use in the past month * psychostimulant or nootropic medication use * current use of supplements or medications for weight loss or following a weight loss program * severe or uncontrolled autoimmune diseases * current or previous diagnosis of severe kidney failure, liver cirrhosis and some pulmonary diseases * heart disease events (including stroke or heart attack) within last 3 months prior to enrollment * alcohol or drug abuse
external beam radiation with intratumoral injection of dendritic cells as neo-adjuvant treatment for sarcoma

Conditions: Soft Tissue Sarcoma

Summary: this is a phase ii study using a combination of external beam radiation with intratumoral injection of dendritic cells (white blood cells) as neo-adjuvant treatment for patients with high-risk soft tissue sarcoma. the purpose was to determine if an injection of the patient's own immune related white blood cells into their tumor would strengthen the immune system to fight against their cancer.

patients were treated with external beam radiation therapy (ebrt) combined with experimental intratumoral injection of dendritic cell (dc). patients received 5,040 centigray (cgy) ebrt in 28 equal fractions. radiation was delivered 5 days per week (monday-friday). dcs (10\^7 cells) were injected intratumorally three times on the second, third, and fourth friday during the course of radiation. one additional dc injection was given several days before surgery to assess dc migration. tumors were surgically resected 3-6 weeks after the completion of ebrt.

Eligibility criteria:
inclusion criteria: * intermediate or high grade sarcoma as determined by pathology review * musculoskeletal tumor in extremities, trunk or chest wall. * primary tumor or isolated locally recurrent tumor greater than 5 cm in diameter. * clinical stage t2n0m0 (ajcc 6th edition) * patient is not a candidate for neoadjuvant chemotherapy. * performance status eastern cooperative oncology group (ecog) 0 or 1. * no steroid therapy within 4 weeks of first dendritic cell administration. * no coagulation disorder. * patient's written informed consent. * no contraindication to resection. * adequate organ function (measured within a week of beginning treatment). * white blood count (wbc) \> 3,000/mm to the third power and absolute neutrophil count (anc) \>1500/mm to the third power * platelets \> 100,000/mm to the third power * hematocrit \> 25% * bilirubin \< 2.0 mg/dl * creatinine \ 60 ml/min * radiation oncologist must confirm that a 2-3 cm strip of skin can be spared from radiation. exclusion criteria: * retroperitoneal location. * gastrointestinal stromal tumor (gist). * demonstrated metastatic disease. * prior radiation therapy if the current tumor is locally recurrent after prior resection. * concurrent treatment with any anticancer agent other than radiation as dictated by the protocol. * bleeding disorder. * h.i.v. infection or other primary immunodeficiency disorder. * ongoing systemic therapy with immunosuppressant drugs (e.g. corticosteroids, azathioprine, cyclosporin, methotrexate). * any serious ongoing infection. * pregnant or lactating women -- patients in reproductive age must agree to use contraceptive methods for the duration of the study (a pregnancy test will be obtained before treatment). * ecog performance status of 2, 3 or 4.

Keywords: sarcoma intratumoral injection dendritic cells neo-adjuvant treatment immunotherapy pheresis radiation
prevalence of pancreatic steatosis in pancreatic cystic neoplasms and pancreatic adenocarcinoma

Conditions: Pancreatic Steatosis; Pancreatic Cyst; Pancreatic Adenocarcinoma

Summary: several pancreatic neoplastic cystic lesions, such as ipmn (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (net) and mucinous neoplasms, present a carcinogenetic risk, though it is yet unknown if this risk is increased in patients with pancreatic steatosis (ps). the primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk. the secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.

pancreatic steatosis has gained significant novel interest in the pathophysiology of pdac and neoplastic cystic lesions. pancreatic steatosis is the new emerging issue in pancreatology. recently, pancreatic steatosis has gained significant novel interest in the pathophysiology of pdac. the primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk. pancreatic ductal adenocarcinoma (pdac) has a poor survival, predominantly as a result of its diagnosis in advanced stages. pathological changes of steatosis are an independent determinant of pdac, and these pathological changes are correlated with the attenuation of the pancreas on computed tomography (ct). the secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.

Eligibility criteria:
inclusion criteria: * age 18 or older * patients with at least 1 pancreatic cystic lesion based on ct and eus features, with a cyst size ≥ 5mm; or healthy subjects or pdac (confirmed by histopathological exam). exclusion criteria: * no evidence of written informed consent * patients with contraindications for endoscopy due to comorbidities * metal stent in hepato-bilio-pancreatic region at time of baseline ct-imaging (vascular, luminal and biliary) * acute pancreatitis at baseline imaging * pancreatic surgery at baseline imaging in our department * splenectomy * patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women

Keywords: pancreas steatosis cyst cancer adenocarcinoma fat
heads: up online psychological self-management intervention: feasibility 2

Conditions: Stroke; CVA (Cerebrovascular Accident); Anxiety; Depression

Summary: to test feasibility of online version of heads: up

study aim(s): to conduct feasibility testing of online heads: up, a tailored adaptation of an existing psychological intervention (mbsr) to help people affected by stroke self-manage symptoms of anxiety and depression. objectives: 1) assess feasibility and acceptability of delivering the heads: up intervention online and identify any additional adaptations to the heads: up manual and supporting materials. 2) assess feasibility and acceptability of online research processes, including recruitment, screening, and obtaining informed consent, and data collection processes. research question: what elements of intervention design, delivery, and study processes require to be optimised ahead of a 3-arm rct?

Eligibility criteria:
inclusion criteria: * aged ≥18 years * have had ≥1 stroke at least 3 months previously * interested in learning skills to help cope with self-reported anxiety and/or depression * able to speak and understand conversational english * score ≥ 4 on either sub-scale hospital anxiety and depression scale (hads) * desirable: able to identify a family member/peer who would: like to take part, can speak and understand conversational english; not participating in another trial. potential participants who do not identify someone else to take part with them will not be excluded. exclusion criteria: * prior mbsr attendance in the last three years (as this may confound results) * current participant in another trial * cannot follow a 2-stage command

Keywords: stroke cva anxiety depression mindfulness mbsr online self-management
a study of rituxan in the treatment of polyneuropathies associated with serum igm autoantibodies

Conditions: Peripheral Neuropathy

Summary: peripheral neuropathies cause weakness and sensory loss that can produce severe disability. some neuropathies are immune-mediated and associated with antibodies. it has been postulated that rituxan treatment may reduce the level of antibody production limiting the loss of muscle strength and hence improve activities of daily living. the purpose of this open-label study (all participants get rituxan and not placebo) is to determine the safety and effectiveness of rituxan in the treatment of polyneuropathies associated with serum igm autoantibodies in those who have already been treated with one course of rituxan. subjects will be treated on the in-patient clinical research center with rituxan for two treatments one week a part and then individual treatments every 10 weeks for one year. the effectiveness of rituxan will be followed by looking for increases in muscle strength and decreases in the serum igm autoantibodies.


Eligibility criteria:
inclusion criteria: * diagnosis of characteristic peripheral neuropathy by appropriate history, physical examination, nerve conduction findings and serum autoantibodies. * serum anti-gm1 on anti-mag antibodies present at high titers in serum, continued by testing in the neuromuscular clinical laboratory at washington university.
efficacy, safety, and pharmacokinetics study of cjm112 in hidradenitis suppurativa patients

Conditions: Hidradenitis Suppurativa (Acne Inversa)

Summary: this is a randomized, double blind, multicenter study in patients with moderate to severe chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of multiple doses of cjm112 in comparison to placebo. the study has two periods to explore preliminary dose effects.


Eligibility criteria:
inclusion criteria: 1. male and female patients 18 to 65 years of age with clinically diagnosed chronic hs for at least 1 year (prior to screening) who have undergone previous antibiotic therapy 2. weight between 50 kg and 150 kg 3. hs-pga score of at least moderate severity at the time of inclusion with at least 4 abscesses and/or nodules. hs lesions must be present in at least two distinct anatomical areas, and at least one area must be minimally hurley stage ii (moderate) exclusion criteria: 1. use of previous biologics or other specified concomitant medications 2. use of any systemic treatment for hs in the last 4 weeks prior to randomization 3. presence of more than 25 draining fistulae. 4. surgical treatment for hs in the last 4 weeks prior to randomization/first treatment. 5. women of child-bearing potential and sexually active males unwilling to use a condom during intercourse while taking drug and for 15 weeks after stopping investigational medication. 6. evidence of active tuberculosis at screening 7. history of severe systemic candida infections or evidence of candidiasis in the last two weeks 8. active systemic or skin infections (other than common cold or hs related) during the two weeks before randomization/first treatment 9. any live vaccines (including nasal spray flu vaccine) starting from 6 weeks before randomization. other protocol-defined inclusion/exclusion criteria may apply

Keywords: hidradenitis suppurativa
repeated eus-guided fine needle biopsy of pancreatic masses after non-diagnostic or inconclusive results

Conditions: Pancreatic Adenocarcinoma; Pancreas Cancer; Pancreas Metastases

Summary: the primary aim of reubio study is to evaluate the diagnostic accuracy of repeated endoscopic ultrasound-guided fine needle biopsy after a previous non-diagnostic or inconclusive eus-guided sampling of solid pancreatic lesions.

endoscopic ultrasound-guided fine needles biopsy (eus-fnb) represents the gold standard method for the diagnosis of solid pancreatic lesions (spls), even if a non-negligible risk of false-negative or inconclusive results still exists. in such cases, major guidelines recommend repeating eus-guided tissue sampling. nevertheless, this recommendation is not based on high-quality evidence and little is known about the performance of repeated eus-fnb (reus-fnb). the primary aim of this study is to evaluate the diagnostic accuracy of reus-fnb after a previous non-diagnostic or inconclusive eus-guided sampling of spls. the secondary aims of this study are to evaluate reus-fnb sensitivity, specificity, positive predictive value, negative predictive value, specimen adequacy, bethesda classification, adverse events incidence and factors that influenced reus-fnb performance.

Eligibility criteria:
inclusion criteria: * age \>18 years old * solid pancreatic mass * previous non diagnostic or inconclusive eus-tissue aquisition exclusion criteria: * age \< 18 years old * pancreatic mass with a predominantly cystic component * previous pancreatic tissue acquisition was not performed under eus-guidance (e.g. percutaneous sampling under abdominal ultrasound-guidance) * repetition of pancreatic tissue sampling, after an inconclusive or non-diagnostic result, obtained by other methods than eus-fnb, such as eus-fna or surgery or percutaneous sampling. * patients with anatomic alterations or hematologic instability (including presence of severe blood clotting disorders) were excluded. * reus-fnb of an extra-pancreatic mass

Keywords: endoscopic ultrasound eus-fnb solid pancreatic lesion
hyperbilirubinemia in acute appendicitis as a predictor of perforation

Conditions: Perforated Appendicitis

Summary: it has recently been published that hyperbilirubinemia is a reliable marker for the preoperative diagnosis of perforated acute appendicitis. the investigators believe, based on their own previous publications, that c-reactive protein (crp) with or without a white blood cell count and some other clinical parameters, are more specific markers for the preoperative diagnosis of perforated acute appendicitis. the purpose of this study is to prospectively compare the specificity and sensitivity of hyperbilirubinemia crp, white blood cell count and other clinical parameters for the preoperative diagnosis of acute appendicitis.

* previously validated appendicitis score * time from onset of symptoms to diagnosis and to surgery * laboratory values: wbc, crp, liver function test * sirs values * preoperative and postoperative diagnosis * length of hospital stay * postoperative complications * biopsy results

Eligibility criteria:
inclusion criteria: * patients scheduled for appendectomies for acute appendicitis at the emergency unit of our institution * patients older than 15 years of age to 100 years of age exclusion criteria: * appendectomy performed incidentally or for other indications * patients younger than 15 years of age * alcoholism * a history of viral hepatitis * gilbert's disease * dubin johnson syndrome * bric (benign recurrent intra-hepatic cholestasis) and other documented biliary * hemolytic or liver diseases associated with hyperbilirubinaemia

Keywords: appendicitis hyperbilirubinemia crp values of bilirubin values of liver function test values of white blood cells values of crp